Surgery is essential for the effective management of bronchiectasis. Segmentectomy, while a challenging procedure, has become ...

Over the past decades, bronchiectasis has been neglected, despite the global burden.1,2 To date, better diagnosis due to easy ...

This study cohort was made up of 71.3% U.K. patients with bronchiectasis. Referral to pulmonary rehabilitation was presented to 19.6% of patients. Prior to being diagnosed with bronchiectasis ...

Find effective medications for 'Bronchiectasis treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic options designed to manage ...

Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and ...

Brensocatib, if approved, would be the first available treatment specifically targeting bronchiectasis, a chronic lung ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for chronic lung disease bronchiectasis in the US. The regulator has set a ...

Considering taking supplements to treat bronchiectasis? Below is a list of common natural remedies used to treat or reduce the symptoms of bronchiectasis. Follow the links to read common uses ...

Shares in Insmed have rocketed after the biotech reported positive results in a highly-anticipated clinical trial of brensocatib in the respiratory disorder bronchiectasis. The phase 3 trial ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $96 from $92 and keeps a Buy rating on the shares. The firm’s ...